SMTISanara MedTech Inc.
Is the business good?
The checks split: nothing decisive, though margins widening.
Operating profit is mostly backed by cash. Conversion is improving vs a year ago.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is SMTI?
Sanara MedTech Inc. earns 17% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 8.1 points above what the capital costs: growth creates value
- Operating margin
- 7.7%
Operating margin · Medical Instruments & Supplies median 6.6% · 12 months to Q2 2026
- Cash conversion
- 0.86×
Cash conversion · 0.73× a year ago · most of the operating profit arrived as cash, working capital took the rest
- Share count, year on year
- −3.0%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | −32% |
| FY2021 | −31% |
| FY2022 | −27% |
| FY2023 | −6.5% |
| FY2024 | 1.5% |
| FY2025 | 7.1% |
Details›
- Gross margin12 months to Q2 2026
- 93%
- Operating margin12 months to Q2 2026
- 7.7%
- Net margin12 months to Q2 2026
- −29%
- Free cash flow margin
- 4.1%
- R&D as % of revenue
- 4.5%
- Revenue, trailing twelve months
- $110M
- Free cash flow, trailing twelve months
- $4.5M
- Net income, trailing twelve months
- −$32M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 17%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Instruments & Supplies
Ranks #13 of 21 by RyuScore